Fidelity Wise Origin Bitcoin Fund amends trust agreement to allow in-kind share transactions
In a turbulent market environment, Health Catalyst Inc. (NASDAQ:HCAT) stock has touched a 52-week low, sinking to $3.75. According to InvestingPro analysis, the company currently appears undervalued, with analysts setting price targets ranging from $5 to $16. The healthcare data and analytics company has faced significant headwinds over the past year, reflected in a stark 1-year change with a decline of 41.64%. Despite these challenges, the company maintains a healthy current ratio of 1.43 and generated positive free cash flow of $12.94 million in the last twelve months. Investors have shown concern as the stock plummeted to this new low, marking a challenging period for the company amidst a broader industry downturn. The 52-week low serves as a critical indicator for the company’s performance and investor sentiment, as Health Catalyst continues to navigate through the evolving healthcare landscape. For deeper insights into HCAT’s financial health and growth prospects, access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
In other recent news, Health Catalyst Inc. reported its financial results for the fourth quarter of 2024, revealing an earnings per share (EPS) of -$0.33, which fell significantly short of the forecasted $0.07. The company’s revenue for the quarter was $79.6 million, slightly below the expected $80.68 million. Despite the earnings miss, Health Catalyst’s adjusted EBITDA for the quarter showed a significant year-over-year increase of 485% to $7.9 million. The company has set its revenue guidance for 2025 at approximately $335 million, with an adjusted EBITDA expectation of around $41 million, slightly above previous estimates.
In terms of strategic moves, Health Catalyst completed the repurchase of approximately $5 million worth of its common stock, as part of a broader $40 million buyback program. The acquisition of Upfront Healthcare led to a 10% stock dilution, which has been a point of concern among investors. However, analysts at William Blair maintained an Outperform rating on the stock, highlighting the potential growth driven by the Ignite data and analytics platform. Meanwhile, BTIG analysts revised the price target for Health Catalyst shares to $10 from $13, retaining a Buy rating. This adjustment follows the company’s earnings report and anticipated improvements in service and technology margins throughout the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.